SynAct Pharma announces that the exercise period for warrants of the TO 2 series will start on July 1, 2020July 1, 2020

SynAct PharmaClinical Stage Biotech Company with focus on Resolution Therapy – A novel approach to fight inflammatory and auto-immune diseases

Lead compound AP1189 in Clinical Phase 2

Press releases

June 30, 2020SynAct Pharma announces that the exercise period for warrants of the TO 2 series will start on July 1, 2020
June 30, 2020SynAct Pharma meddelar att nyttjandeperioden för teckningsoptioner av serie TO 2 inleds den 1 juli 2020
June 29, 2020SynAct Pharma has initiated the Phase II clinical study with AP1189 in Nephrotic Syndrome
June 25, 2020SynAct Pharma’s Board of Directors and management sign subscription commitment for warrant exercise of series TO 2

All press releases

News

April 2, 2020BIOSTOCK: Synact Pharma on expansion into Covid-19 (also available in Swedish)
April 1, 2020Synact Pharma in spotlightanalysen (in Swedish)
October 28, 2019Redeye: Adding an indication
July 5, 2019Kliniska bevis för behandlingseffekter av melanokortiner vid reumatoid artrit

Calendar

October 8, 2020Sedermeradagen Gothenburg
October 26, 2020 - October 28, 2020Bio Europe 2020
November 16, 2020Sedermeradagen Stockholm

Subscribe to our press releases